ReviewAmerican journal of cancer research2019
Compound-therapy based on cancer-immunity cycle: promising prospects for antitumor regimens.
Review in American journal of cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Recent Advances in the Application of Cucurbitacin B as an Anticancer Agent.International journal of molecular sciences · 2025Review
- Synergistic combination therapy using cowpea mosaic virus intratumoral immunotherapy and Lag-3 checkpoint blockade.Cancer immunology, immunotherapy : CII · 2024Article
- Comprehensively analysis of immunophenotyping signature in triple-negative breast cancer patients based on machine learning.Frontiers in pharmacology · 2023Article
- Combination of CTLA-4 blockade with MUC1 mRNA nanovaccine induces enhanced anti-tumor CTL activity by modulating tumor microenvironment of triple negative breast cancer.Translational oncology · 2022Article
- Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies.Journal for immunotherapy of cancer · 2022Review
- Comprehensive Analysis of a Cancer-Immunity Cycle-Based Signature for Predicting Prognosis and Immunotherapy Response in Patients With Colorectal Cancer.Frontiers in immunology · 2022Article
- Review
- Immune checkpoint inhibitors in ovarian cancer: where do we stand?Therapeutic advances in medical oncology · 2021Review
- Decoding cancer's camouflage: epithelial-mesenchymal plasticity in resistance to immune checkpoint blockade.Cancer drug resistance (Alhambra, Calif.) · 2020Review
- Prostaglandin E Receptor 4 Antagonist in Cancer Immunotherapy: Mechanisms of Action.Frontiers in immunology · 2020Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunotherapy has made a significant impact on the survival of patients with different tumor. However, it has become clear that they are not sufficiently active durable responses for many tumor patients, but only in a fraction of tumor patients. In order to improve this, combination regimens revealed impressive synergistic effects by combination of doublet or triplet immune agents. In this article, we will summarize the cancer-immunity cycle (CIC) and propose a rationale for the design of synergistic antitumor combinations. In addition, key issues in the development of these strategies are further discussed. Overall, we wish to highlight the backbone principles of combination regimens design at different points of the CIC, with the ultimate goal to guide better designs for future cancer combination therapies.
Indexed as
Identifiers
30906623PMC6405975What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.